Metastatic extrauterine gestational choriocarcinoma of the cecum mimicking ruptured ectopic pregnancy: A case report Authors: Ravi Desai, Cyrus Jalai, Pelin Onur, Chuanyong Lu, Juan Diaz Quinones, Matthew Cowan Published: 2026 ABSTRACT Highlights•Extra-uterine gestational choriocarcinoma should be considered in cases of elevated β-hCG and no intrauterine pregnancy.•Surgical resection is generally avoided however it may be necessary for hemostasis or isolated chemoresistant disease.•Prompt intervention – both chemotherapeutic and/or surgical – is critical for reducing both morbidity and mortality. Introduction Gestational choriocarcinoma (GC) is an uncommon malignancy, with an estimated incidence of approximately 2–7 cases per 100,000 pregnancies in the United States, yet it represents one of the most aggressive forms of gestational trophoblastic neoplasia (GTN) (Smith et al., 2003, Lurain, 2010). Epidemiologic studies demonstrate that roughly half of cases arise following a hydatidiform mole, while approximately one-quarter occur after a normal term pregnancy, with the remainder developing after spontaneous or induced abortion or ectopic gestation (Lurain, 2010, Berkowitz and Goldstein, 2009, Seckl et al., 2010). Although many cases are detected early because of abnormal vaginal bleeding, up to 30 % of patients present with metastatic disease at initial diagnosis, most commonly involving the lungs, vagina, brain, or liver (Lurain, 2010, Ngan et al., 2025 Sep). This metastatic burden necessitates multi-agent, and often more toxic chemotherapy regimens, posing significant short- and long-term implications for a predominantly young, reproductive-age population. Importantly, GC remains among the most chemotherapy-responsive solid tumors, with complete remission rates exceeding 85–90 %; therefore, recognition of atypical or subtle clinical presentations is critical to facilitate timely referral and initiation of oncologic care (Lurain, 2010, Ngan et al., 2025 Sep, FIGO Oncology Committee, 2002). The clinical presentation of GC is highly heterogeneous; a systematic review describes an age range at diagnosis of 17–67 years and reports that some patients present with primary cardiopulmonary or central nervous system symptoms rather than gynecologic complaints, with subsequent workup leading to diagnosis.(Mangili et al., 2014) Extrauterine choriocarcinoma is itself rare and has been reported to arise from the ovaries, fallopian tubes, or other pelvic sites, while nongestational choriocarcinoma represents an even rarer entity derived from multipotent cells along the germ cell migration pathway (Saha et al., 2012, Malovrh et al., 2023 Feb 11, Smith, 2003). In this report, we describe abdominal extrauterine choriocarcinoma involving the cecum that clinically mimicked a ruptured ectopic pregnancy. Recognition and reporting of such atypical presentations are essential for all OB/GYN providers to facilitate earlier diagnosis and optimize outcomes. Case presentation A 36-year-old G6P4 presented to Family Planning for evaluation of an undesired pregnancy after a positive urine pregnancy test. The patient reported a positive urine pregnancy test two months prior to presentation. She experienced period-like vaginal bleeding one month later which was presumed to be a miscarriage; however, a repeat pregnancy test one month after the bleeding episode remained positive, prompting clinic evaluation. Initial transvaginal ultrasound demonstrated an anteverted uterus with a 6.7-mm endometrial echo, normal-appearing ovaries, and no free fluid. She declined in-office diagnostic manual vacuum aspiration and instead opted for surveillance with serum β-hCG testing. She additionally had placement of an etonogestrel subdermal implant for contraception. Her serum β-hCG returned markedly elevated at 455,501 mIU/mL. Despite absence of bleeding or cramping, she was referred to the Emergency Department for further evaluation. In the Emergency Department, she was initially hemodynamically stable. Repeat transvaginal ultrasound demonstrated no intrauterine pregnancy, an enlarged right ovary with an adjacent 2.4 × 2.2 × 2.4-cm thick-walled structure concerning for hemorrhagic corpus luteum versus ectopic pregnancy, and a large volume of pelvic hemoperitoneum (Fig. 1A). The examination was aborted when the patient briefly lost consciousness and developed hypotension (90/66 mmHg) with diaphoresis and lethargy. She was emergently taken to the operating room for presumed ruptured tubal vs abdominal ectopic pregnancy.Fig. 1Pre-operative transvaginal ultrasonography; (A/B) sagittal view of the uterus without identifiable intra-uterine pregnancy; (C) Transverse pelvic view with complex hemorrhagic contents concerning for hemoperitoneum.Fig. 1 Pre-operative transvaginal ultrasonography; (A/B) sagittal view of the uterus without identifiable intra-uterine pregnancy; (C) Transverse pelvic view with complex hemorrhagic contents concerning for hemoperitoneum. Dilation and curettage was performed followed by diagnostic laparoscopy, which revealed approximately 500 mL of hemoperitoneum, but normal uterus, fallopian tubes and ovaries. Also, the pouch of Douglas and mesosalpinx were free of implantation (Fig. 2A-B). An isolated peri-cecal mass overlying the appendix with gross appearance suggestive of an ectopic pregnancy was identified (Fig. 2C). With assistance from general surgery, the mass was successfully dissected free from the cecum without evidence of mucosal invasion.Fig. 2Intraoperative laparoscopic pelvic evaluation. (A) Normal appearing left fallopian tubes and ovary with uterine fundus; (B) Normal appearing right fallopian tubes and ovary; (C) Peri-cecal choriocarcinoma with active hemorrhage.Fig. 2 Intraoperative laparoscopic pelvic evaluation. (A) Normal appearing left fallopian tubes and ovary with uterine fundus; (B) Normal appearing right fallopian tubes and ovary; (C) Peri-cecal choriocarcinoma with active hemorrhage. Final pathology demonstrated atypical trophoblastic proliferation within the uterine contents and choriocarcinoma within the cecal mass, without chorionic villi or fetal tissue identified (Fig. 3A). The tumor consisted of mononucleated trophoblasts and syncytiotrophoblasts with marked cytologic atypia, frequent mitoses, focal necrosis, and a high proliferative index (Ki-67 up to 80 %, Fig. 3B-C).Fig. 3Histopathologic Examination; (A) Solid sheets of atypical syncytiotrophoblasts, cytotrophoblasts, and intermediate trophoblasts in the absence of chorionic villi. (B) Tumor cells showing significant cytologic atypia and occasional mitotic figures. (C) Immunohistochemical staining for Ki-67 highlights a markedly elevated proliferative index of up to 80 %.Fig. 3 Histopathologic Examination; (A) Solid sheets of atypical syncytiotrophoblasts, cytotrophoblasts, and intermediate trophoblasts in the absence of chorionic villi. (B) Tumor cells showing significant cytologic atypia and occasional mitotic figures. (C) Immunohistochemical staining for Ki-67 highlights a markedly elevated proliferative index of up to 80 %. Before histopathologic confirmation, the patient received two empiric doses of intramuscular methotrexate for presumed ectopic pregnancy. After diagnosis, CT scan of the chest, abdomen, and pelvis demonstrated no suspicious sites of additional metastatic disease. Atypical trophoblastic proliferation on uterine curettage established the uterus as the primary site, with the peri-cecal mass representing a single site of metastasis. As this involved a gastrointestinal site (a non-pulmonary, non-genital metastasis) the patient was classified as FIGO stage IV. A WHO prognostic score of 10 was calculated as follows: age < 40 (0 points), spontaneous abortion as the antecedent pregnancy (1 point), interval from antecedent pregnancy of less than 4 months (0 points), β-hCG > 100,000 mIU/mL at diagnosis (4 points), largest tumor size > 5 cm (2 points), one site of metastatic disease (1 point), gastrointestinal site of metastasis (2 points), and no prior chemotherapy (0 points). Given stage IV disease with WHO score ≥ 7, she was treated with multi-agent chemotherapy (EMA-CO) every 14 days: etoposide 100 mg/m2 IV on days 1–2, methotrexate 100 mg/m2 IV bolus followed by 200 mg/m2 continuous infusion over 12 h on day 1, and actinomycin D 0.5 mg IV bolus on days 1–2, followed by cyclophosphamide 600 mg/m2 IV and vincristine 1.0 mg/m2 IV on day 8. Leucovorin 15 mg orally every 12 h for four doses was administered after methotrexate. She completed five total cycles of EMA-CO, including three consolidation cycles after β-hCG normalization. Treatment was complicated by persistent transaminitis during cycle 2, prompting methotrexate dose reduction to 50 mg IV bolus plus 100 mg over 12 h for cycle 3, and by grade 2 peripheral neuropathy requiring vincristine dose reduction to 0.8 mg/m2 starting cycle 4. At this time, she has been undergoing surveillance with monthly β-hCG measurement for three months and has no evidence of disease. Her chemotherapy toxicities have resolved. Discussion This case illustrates an exceptionally rare presentation of extra-uterine gestational choriocarcinoma manifesting as a peritoneal mass and clinically mimicking a ruptured ectopic pregnancy requiring emergent surgical intervention. Our patient presented with signs of hemoperitoneum and a markedly elevated β-hCG level in the absence of an intrauterine pregnancy on imaging. In this scenario, β-hCG levels exceeding 100,000 mIU/mL are atypical for most ectopic pregnancies and therefore gestational trophoblastic disease (GTD) should be highest on the differential. Within the GTD spectrum, the primary entities to consider are molar pregnancy, invasive mole, and gestational choriocarcinoma. Molar pregnancy is the most common of these. The absence of intrauterine pathology on transvaginal ultrasound made this less likely, though ectopic molar pregnancies presenting with hemorrhage have been reported (Aravapalli et al., 2024). Invasive hydatidiform mole, the most common malignant form of GTD, was the next consideration. Invasive mole is most often a clinical diagnosis once postmolar GTN criteria are met on β-hCG surveillance however cases of hemoperitoneum have been reported from perforation of the uterus (Grin et al., 2017) and bleeding from intestinal metastases (Yu et al., 2025) requiring surgical intervention which therefore provides pathologic confirmation. Gestational choriocarcinoma, the second most common malignant form of GTD, was also high on the differential. Although most commonly preceded by molar gestation, a substantial minority follow nonmolar intrauterine pregnancies or ectopic gestations, with up to 30 % presenting with metastatic disease at time of diagnosis (Lurain, 2010, Seckl et al., 2010). Choriocarcinoma more commonly has pathologic confirmation as compared to invasive moles, typically from uterine curettage, although clinical diagnosis is frequently made in patients with markedly elevated β-hCG, characteristic imaging findings, and history of an antecedent pregnancy (Lurain, 2010). Choriocarcinoma is particularly hemorrhage-prone relative to invasive moles given its aggressive vascular invasion and absence of chorionic villi, which in molar disease provide some degree of structural support; hemorrhage from metastatic sites remains the leading cause of morbidity and mortality for choriocarcinoma (Berkowitz and Goldstein, 1996). The patient's hemodynamic decompensation appropriately prioritized emergent surgical management. Intraoperative identification of a peri-cecal mass with histopathologic confirmation of choriocarcinoma underscores the capacity of GC to implant at unusual extrauterine sites and highlights the diagnostic challenge such presentations pose. It bears emphasis that in most circumstances, biopsy of suspected metastatic GTN lesions should be avoided given their high vascularity and risk of catastrophic hemorrhage. While chemotherapy is the cornerstone of GC treatment, surgery plays a selective adjunctive role in securing hemostasis, establishing tissue diagnosis, or resecting isolated chemoresistant disease. Hysterectomy is not routinely performed, but in uterine-confined disease it can be considered alongside chemotherapy, as it has been shown to shorten time to β-hCG normalization and reduce the total number of chemotherapy cycles required (Larsson et al., 2025). Importantly, hysterectomy does not obviate systemic chemotherapy, which should be initiated promptly given the disease's exquisite chemosensitivity. In this case, surgical intervention provided both hemostasis and tissue diagnosis, enabling timely initiation of multi-agent chemotherapy for high-risk disease. Although histologic confirmation of choriocarcinoma was obtained from the cecal mass rather than the uterine curettage specimen, the uterus was suspected to be the primary site on clinical grounds. This is consistent with a recognized phenomenon in which the uterine primary undergoes spontaneous regression or involution while metastatic implants continue to progress. Cases of metastatic gestational choriocarcinoma presenting without identifiable uterine disease or gynecologic symptoms have been well described (Geravandi et al., 2024, Pahwa et al., 2023). The atypical trophoblastic proliferation identified on uterine curettage likely represents residual involuting primary disease, explaining the absence of discrete uterine pathology on imaging. This underscores a critical diagnostic challenge: not all patients with gestational choriocarcinoma will present with abnormal uterine bleeding or visible uterine lesions on imaging, and the absence of either should not exclude the diagnosis. Reproductive-aged patients with disproportionately elevated β-hCG, atypical imaging findings, or extrauterine masses warrant urgent consideration of GTN and prompt oncologic referral. Early initiation of chemotherapy is associated with cure rates exceeding 85–90 % even in advanced-stage disease, and earlier initiation reduces cumulative chemotherapy exposure and long-term treatment sequelae. This case expands the literature on rare GC presentations and reinforces the importance of multidisciplinary management in optimizing survival and preserving long-term health in this patient population. Consent for publication Written informed consent was obtained from the patient for publication of this case report and any accompanying images. CRediT authorship contribution statement Ravi Desai: Writing – review & editing, Writing – original draft, Formal analysis, Data curation, Conceptualization. Cyrus Jalai: Writing – review & editing, Writing – original draft, Formal analysis, Data curation, Conceptualization. Pelin Onur: Writing – original draft, Formal analysis, Data curation. Chuanyong Lu: Formal analysis, Data curation. Juan Diaz Quinones: Writing – review & editing, Writing – original draft, Supervision, Formal analysis, Conceptualization. Matthew Cowan: Writing – review & editing, Writing – original draft, Supervision, Formal analysis, Data curation, Conceptualization. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.